Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
| ▸ | CTSC | P53634 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.35 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | TLR2 | O60603 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29531712 | 0.92 | PRCP (0.42) | PRCPDPP7MEN1KMT2AGHSR | |
| SCHEMBL31019315 | 0.91 | PRCP (0.41) | PRCPDPP7MEN1KMT2AGHSR | |
| SCHEMBL30193521 | 0.90 | MEN1 (0.45) | PRCPDPP7MEN1KMT2AGHSR | |
| SCHEMBL29947667 | 0.89 | EED (0.41) | PRCPDPP7MEN1KMT2AGHSR | |
| SCHEMBL31572023 | 0.88 | MEN1 (0.48) | PRCPDPP7MEN1KMT2ACTSC | |
| SCHEMBL30193454 | 0.87 | PRCP (0.44) | PRCPDPP7MEN1KMT2ACALCRL | |
| SCHEMBL30416888 | 0.87 | MAPK8 (0.42) | PRCPDPP7MEN1KMT2ACALCRL | |
| SCHEMBL29531751 | 0.86 | DPP7 (0.45) | PRCPDPP7MEN1KMT2AGHSR | |
| SCHEMBL30713450 | 0.86 | DPP7 (0.45) | PRCPDPP7MEN1KMT2AGHSR | |
| SCHEMBL30193219 | 0.85 | MEN1 (0.42) | PRCPDPP7MEN1KMT2AHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | claimed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | claimed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | claimed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | claimed |
| EP-4713025-A2 | DELIVERY OF DUAL PAYLOAD OF MMAF OR MMAE AND TLR7 AGONISTS | The Research Foundation for The State University of New York (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4301417-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | The Research Foundation for The State University of New York (US) | 2024-01-10 | — | — | EP | disclosed |
| WO-2022187809-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2022-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189440-A1 | TLR7 AND TLR8 AGONISTS FOR THE TREATMENT OF CANCER AND/OR INFECTIOUS DISEASES | TLR7, TLR8, TLR9 | PRCP 1840/4885DPP7 1361/4885MEN1 4422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.